Skip to content

Effects of Short-term Curcumin and Multi-polyphenol Supplementation on the Anti-inflammatory Properties of HDL

Effects of Short-term Curcumin and Multi-polyphenol Supplementation on the Anti-inflammatory Properties of HDL

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02998918
Acronym
PSI
Enrollment
21
Registered
2016-12-21
Start date
2016-09-30
Completion date
2020-06-30
Last updated
2023-11-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Inflammation, Atherosclerosis, Cardiovascular Disease

Keywords

Inflammation, HDL, Anti-inflammatory, Supplementation, Curcumin, polyphenol, V-cam, I-cam, atherosclerosis, cardiovascular disease, atherogenesis, antioxidant, resveratrol, quercetin

Brief summary

Polyphenol supplements, including curcumin and resveratrol, are known to decrease inflammation, but previous polyphenol supplements were poorly absorbed and thus their effects were reduced. A new phytosome formulation coats the supplements and allows them to be better absorbed. The purpose of this study is to examine the acute (1-hr) and short-term (1-week) effects of two different phytosome-formulated polyphenol supplements on inflammation. The two supplements that will be used are: 1) PolyResveratrol and 2) Curcumin.

Detailed description

Atherosclerosis is a chronic inflammatory disease underlying coronary artery disease, driven in part by the innate immune system, particularly macrophages. The adhesion of leukocytes to the vascular endothelium, mediated by endothelial cellular adhesion molecules including vascular adhesion molecule-1 (VCAM-1) and intercellular adhesion molecule-1 (ICAM-1), is one of the crucial initial steps in atherogenesis. Elevated levels of high-density lipoprotein cholesterol (HDL-C) are associated with reduced risk for cardiovascular disease (CVD); however, interventions designed to increase HDL-C concentration in humans have yet to lead to reductions in cardiovascular events. A possible explanation for the failure of recent clinical trials is the structural and functional complexity of HDL particles, which have multiple cardioprotective properties, including anti-inflammatory, antioxidative, and reverse cholesterol transport activities. The anti-inflammatory effects of HDL include reduction of inflammatory cytokines and vascular leukocyte adhesion molecules. A recent study showed that dietary composition can affect HDL's anti-inflammatory properties, namely the ability to inhibit the expression of ICAM-1 and VCAM-1. Numerous studies have shown that polyphenols, including curcumin, quercetin, and resveratrol, exhibit multiple health benefits, including anti-inflammatory properties. Curcumin is a flavonoid polyphenol that is the active ingredient in the spice turmeric. Quercetin is one of the most abundant dietary flavonoids and is found in many fruits, vegetables, and beverages. Resveratrol is a non-flavonoid polyphenol present in a limited number of plant-derived foods, including grapes and peanuts. In vitro studies show these three polyphenols independently decrease VCAM-1 and ICAM-1 expression induced by tumor necrosis factor alpha (TNFα) in human endothelial cells, as well as increase cholesterol efflux to apolipoprotein A-I (apoA-I) and HDL in macrophages. However, previous in vitro models used direct incubation with each polyphenol (i.e., HDL was directly exposed to the polyphenol in the cell culture, as opposed to incubation with plasma after consumption of the polyphenol), with doses much higher than found in typical human diets or supplements. The health effects of polyphenols in humans are limited by their poor bioavailability, as they are rapidly metabolized and excreted. Recent studies have found that formulating poorly-absorbed molecules with phosphatidylcholine via phytosomes increases their bioavailability. For example, recent studies comparing curcumin phytosome (Meriva®) and standard curcumin formulations in humans found that the curcumin phytosome formulation increased curcuminoid bioavailability between 8- to 29-fold. To our knowledge, no study has examined the effects of polyphenol supplementation, particularly phytosome-formulated polyphenols, in humans on the ability of circulating plasma to inhibit the expression of cellular adhesion molecules or enhance cholesterol efflux capacity in vitro. Furthermore, it is unknown whether polyphenol supplementation modulates the ability of HDL particles to perform these same functions. Therefore, the purpose of this study is to examine whether acute and short-term (1-week) polyphenol supplementation in humans affects inflammation measured at the whole plasma level, as well as the inflammatory and cholesterol efflux properties of HDL particles. The investigators will test the effects of two supplements in a cross-over design: a curcumin phytosome and a multi-polyphenol supplement (containing curcumin phytosome, quercetin phytosome, and trans-resveratrol). The investigators hypothesize that one of the mechanisms by which polyphenols exert a beneficial effect on inflammation and atherosclerosis is through its modulation of HDL particles.

Interventions

DIETARY_SUPPLEMENTPolyResveratrol Supplementation

Participants will take 1 mg of a polyresveratrol phytosome supplement each day for one week. The acute effect (1 hr) of one 500 mg dose of the polyresveratrol phytosome supplement on inflammation will be examined along with the short-term effect (1 week).

DIETARY_SUPPLEMENTCurcumin Supplementation

Participants will take 1 mg of a curcumin phytosome supplement each day for one week. The acute effect (1 hr) of one 500 mg dose of the curcumin phytosome supplement on inflammation will be examined along with the short-term effect (1 week).

Sponsors

University of South Carolina
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
Yes

Inclusion criteria

* General good health * Between 18 and 60 years old * Non-smoker * Not taking any medications or dietary supplements

Exclusion criteria

* Taking prescription anti-inflammatory drugs or supplements/drugs that may affect inflammation

Design outcomes

Primary

MeasureTime frameDescription
Inflammation Change: HDL PlasmaOne weekVCAM-1 expression in HDL plasma will be measured at baseline, and after one week of supplementation for each supplement. Differences in one-week changes in inflammation between each supplement will be compared.

Countries

United States

Participant flow

Participants by arm

ArmCount
Group 1: PolyResveratrol Then Curcumin Supplementation
Group 1 consumed 1 mg/day (one dose of 500 mg/two capsules in morning and two capsules/500 mg at night) of Polyresveratrol-SR for one week in phase 1 then after a 2-week washout period consumed 1 mg/day (one dose of 500 mg/two capsules in morning and one dose of 500 mg at night) of Meriva 500-SF (curcumin phytosome) for one week during phase 2 of the crossover trial
11
Group 2: Curcumin Then PolyResveratrol Supplementation
Group 2 consumed 1 mg/day (one dose of 500 mg/two capsules in morning and two capsules/500 mg at night) of Meriva 500-SF (curcumin phytosome) for one week in phase 1 then after a 2-week washout period consumed 1 mg/day (one dose of 500 mg/two capsules in morning and one dose of 500 mg at night) of Polyresveratrol-SR for one week during phase 2 of the crossover trial
10
Total21

Withdrawals & dropouts

PeriodReasonFG000FG001
Overall StudyWithdrawal by Subject10

Baseline characteristics

CharacteristicGroup 1: PolyResveratrol Then Curcumin SupplementationGroup 2: Curcumin Then PolyResveratrol SupplementationTotal
Age, Continuous26.8 years
STANDARD_DEVIATION 6.3
30.0 years
STANDARD_DEVIATION 7.4
28.0 years
STANDARD_DEVIATION 6.9
BMI24.2 kg/m^2
STANDARD_DEVIATION 4.5
25.0 kg/m^2
STANDARD_DEVIATION 5
24.4 kg/m^2
STANDARD_DEVIATION 4.6
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Asian
1 Participants0 Participants1 Participants
Race (NIH/OMB)
Black or African American
0 Participants0 Participants0 Participants
Race (NIH/OMB)
More than one race
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants0 Participants0 Participants
Race (NIH/OMB)
White
10 Participants10 Participants20 Participants
Region of Enrollment
United States
11 participants10 participants21 participants
Sex: Female, Male
Female
6 Participants5 Participants11 Participants
Sex: Female, Male
Male
5 Participants5 Participants10 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 210 / 20
other
Total, other adverse events
0 / 210 / 20
serious
Total, serious adverse events
0 / 210 / 20

Outcome results

Primary

Inflammation Change: HDL Plasma

VCAM-1 expression in HDL plasma will be measured at baseline, and after one week of supplementation for each supplement. Differences in one-week changes in inflammation between each supplement will be compared.

Time frame: One week

ArmMeasureValue (MEAN)
Group 1: PolyResveratrol Then Curcumin SupplementationInflammation Change: HDL PlasmaNA AU
Group 2: Curcumin Then PolyResveratrol SupplementationInflammation Change: HDL PlasmaNA AU

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026